Cost-Effectiveness Analysis of Sintilimab Plus Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer : A Societal Perspective
© 2024. The Author(s), under exclusive licence to Springer Healthcare Ltd., part of Springer Nature..
INTRODUCTION: The updated ORIENT-11 study demonstrated that sintilimab, when combined with chemotherapy, had promising survival advantage compared to standard chemotherapy alone in the first-line treatment for previously untreated, locally advanced or metastatic non-squamous non-small cell lung cancer (nsNSCLC). This study aims to evaluate the cost-effectiveness of sintilimab plus chemotherapy for advanced nsNSCLC from a Chinese societal perspective.
METHODS: A partitioned survival model with a embedded decision tree was developed to assess the economic value of sintilimab plus chemotherapy over a lifetime horizon. Clinical data was captured from the updated ORIENT-11 study, while costs, health productivity losses, and utility values were collected from a nationwide cross-sectional survey in tertiary hospitals across multiple provinces in China. The primary outcomes were measured using the metrics of quality-adjusted life years (QALYs) and incremental cost-effectiveness ratios (ICER). Costs and health outcomes were discounted at an annual rate of 5% per annum. Sensitivity analyses, including one-way and probabilistic sensitivity analyses, subgroup analyses, and scenario analyses, were performed.
RESULTS: Compared to standard chemotherapy, treatment with sintilimab plus chemotherapy incurred a mean total cost of $23,979 and gained 0.98 QALYs over the lifetime horizon, resulting in an ICER of $24,568 per QALY gained. The use of sintilimab accumulated direct non-medical costs of $9262 and indirect costs of $6780 over 16 years. Probabilistic sensitivity analyses showed an 84.2% probability of sintilimab plus chemotherapy being cost-effective at a threshold of three times China's per capita gross domestic product in 2022 ($38,201). The model was most sensitive to the discount rate of QALYs and costs, as well as the costs of pemetrexed, sintilimab, and subsequent therapy in progressive disease state. Subgroup analyses indicated favorable incremental net monetary benefits in all subgroups.
CONCLUSION: Sintilimab plus chemotherapy is a cost-effective first-line treatment therapy for advanced nsNSCLC in China when compared to standard chemotherapy. These findings, along with the improved progression-free survival and overall survival (OS) observed in ORIENT-11, support the use of this regimen in eligible candidates for advanced nsNSCLC.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - volume:41 |
---|---|
Enthalten in: |
Advances in therapy - 41(2024), 4 vom: 22. März, Seite 1436-1449 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Li, Fuming [VerfasserIn] |
---|
Links: |
---|
Themen: |
8FU7FQ8UPK |
---|
Anmerkungen: |
Date Completed 25.03.2024 Date Revised 25.03.2024 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1007/s12325-024-02808-x |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM368462137 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM368462137 | ||
003 | DE-627 | ||
005 | 20240325234844.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240215s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s12325-024-02808-x |2 doi | |
028 | 5 | 2 | |a pubmed24n1346.xml |
035 | |a (DE-627)NLM368462137 | ||
035 | |a (NLM)38356107 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Li, Fuming |e verfasserin |4 aut | |
245 | 1 | 0 | |a Cost-Effectiveness Analysis of Sintilimab Plus Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer |b A Societal Perspective |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 25.03.2024 | ||
500 | |a Date Revised 25.03.2024 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2024. The Author(s), under exclusive licence to Springer Healthcare Ltd., part of Springer Nature. | ||
520 | |a INTRODUCTION: The updated ORIENT-11 study demonstrated that sintilimab, when combined with chemotherapy, had promising survival advantage compared to standard chemotherapy alone in the first-line treatment for previously untreated, locally advanced or metastatic non-squamous non-small cell lung cancer (nsNSCLC). This study aims to evaluate the cost-effectiveness of sintilimab plus chemotherapy for advanced nsNSCLC from a Chinese societal perspective | ||
520 | |a METHODS: A partitioned survival model with a embedded decision tree was developed to assess the economic value of sintilimab plus chemotherapy over a lifetime horizon. Clinical data was captured from the updated ORIENT-11 study, while costs, health productivity losses, and utility values were collected from a nationwide cross-sectional survey in tertiary hospitals across multiple provinces in China. The primary outcomes were measured using the metrics of quality-adjusted life years (QALYs) and incremental cost-effectiveness ratios (ICER). Costs and health outcomes were discounted at an annual rate of 5% per annum. Sensitivity analyses, including one-way and probabilistic sensitivity analyses, subgroup analyses, and scenario analyses, were performed | ||
520 | |a RESULTS: Compared to standard chemotherapy, treatment with sintilimab plus chemotherapy incurred a mean total cost of $23,979 and gained 0.98 QALYs over the lifetime horizon, resulting in an ICER of $24,568 per QALY gained. The use of sintilimab accumulated direct non-medical costs of $9262 and indirect costs of $6780 over 16 years. Probabilistic sensitivity analyses showed an 84.2% probability of sintilimab plus chemotherapy being cost-effective at a threshold of three times China's per capita gross domestic product in 2022 ($38,201). The model was most sensitive to the discount rate of QALYs and costs, as well as the costs of pemetrexed, sintilimab, and subsequent therapy in progressive disease state. Subgroup analyses indicated favorable incremental net monetary benefits in all subgroups | ||
520 | |a CONCLUSION: Sintilimab plus chemotherapy is a cost-effective first-line treatment therapy for advanced nsNSCLC in China when compared to standard chemotherapy. These findings, along with the improved progression-free survival and overall survival (OS) observed in ORIENT-11, support the use of this regimen in eligible candidates for advanced nsNSCLC | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Cost-effectiveness analysis | |
650 | 4 | |a Costs and cost analysis | |
650 | 4 | |a Immunotherapy | |
650 | 4 | |a Non-small cell lung cancer | |
650 | 4 | |a Sintilimab | |
650 | 7 | |a sintilimab |2 NLM | |
650 | 7 | |a 8FU7FQ8UPK |2 NLM | |
650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
700 | 1 | |a Chen, Yingyao |e verfasserin |4 aut | |
700 | 1 | |a Xiao, Dunming |e verfasserin |4 aut | |
700 | 1 | |a Jiang, Shan |e verfasserin |4 aut | |
700 | 1 | |a Yang, Yi |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Advances in therapy |d 1990 |g 41(2024), 4 vom: 22. März, Seite 1436-1449 |w (DE-627)NLM085859427 |x 1865-8652 |7 nnns |
773 | 1 | 8 | |g volume:41 |g year:2024 |g number:4 |g day:22 |g month:03 |g pages:1436-1449 |
856 | 4 | 0 | |u http://dx.doi.org/10.1007/s12325-024-02808-x |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 41 |j 2024 |e 4 |b 22 |c 03 |h 1436-1449 |